Human leukocyte antigen class I and class II molecules presenting Human Papillomavirus type 52 L1 epitopes (HLA-HPV52-L1)

The Human leukocyte antigen (HLA) class I and class II molecules presenting Human Papillomavirus type 52 (HPV52) L1 epitopes constitute a vital molecular complex for the immune surveillance of high-risk HPV infections (Source: PubMed PMID: 23630115). HPV52 is a major contributor to cervical cancer and its precursors, especially in Asian regions, making its recognition by the immune system a priority for therapeutic intervention (Source: PubMed PMID: 25483456). HLA Class I molecules present L1-derived peptides to CD8+ cytotoxic T cells to trigger the direct lysis of infected cells, while HLA Class II molecules present these epitopes to CD4+ T cells to coordinate the broader immune response and support B-cell antibody production (Source: NIH/NCBI). While prophylactic vaccines like the 9-valent HPV vaccine primarily aim to generate neutralizing antibodies against the L1 protein, the HLA-presented epitopes are the targets for cellular immunity and potential therapeutic vaccines (Source: FDA/Gardasil 9 Label). Therapeutic development focusing on these complexes aims to overcome persistent infections that have already bypassed initial antibody defenses. However, the effectiveness of such therapies is often limited by the vast diversity of HLA alleles in the human population and the virus's ability to evade detection by downregulating HLA expression on the cell surface (Source: PubMed PMID: 21835940).

Other names

HLA-HPV52 L1 complexMHC-restricted HPV52 L1 epitopespMHC HPV52 L1

Presentation of viral epitopes to T-cell receptors (TCRs) to induce cellular immune responses against HPV52-infected cells (Source: PubMed PMID: 23630115).